65,437 trials
ADHD
Primary: Conners' Adult ADHD Rating Scales (CAARS™) — -12; -8.93 units on a scale — p=0.0093
Hypertriglyceridemia · HIV Infection
Primary: Proportion of Subjects With Triglycerides <200 mg/dL — 12 participants
Vasomotor Symptoms · Hot Flashes
Primary: Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value) — -54.515; -54.125; -44.389; -30.020 Hot Flushes per week — p=<0.0001
HIV Infection · Cardiovascular Disease Risk
Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants
Hepatitis C
Primary: Area Under the Concentration Curve (AUC) From Hour 0 to the Final Quantifiable Sample (AUCtf) for Boceprevir Tablets Versus Capsules in Fed State — 7385; 6644 ng*hr/mL
Chronic Pain · Low Back Pain
Primary: The Primary Endpoint is Defined as the Change of the Average Pain Intensity Score on an 11-point NRS-3 at Week 6 From Week -1 (Baseline). — -2.8 Units on a scale
Rheumatoid Arthritis
Primary: Percentage of Participants Experiencing at Least One Serious Adverse Event (SAE) During the 24 Week Treatment Period — 5.8; 8.0; 8.4 Percentage of Participants
Infections, Rotavirus
Primary: Number of Seroconverted Subjects for Serum Anti-rotavirus Immunoglobulin A (IgA) Antibody. — 15 Subjects
Lymphoma, Non-Hodgkin
Primary: Number of Participants Who Received the Therapeutic Dose at the Seven Clinical Research Sites — 7; 8; 8; 5 participants
Smoking
Primary: Smoking Cessation — 29 percentage of participants abstinent
Major Depressive Disorder (MDD)
Primary: Mean Maximum Nausea Severity, Association for Methodology and Documentation in Psychiatry (AMDP-5) Adverse Event (AE) Scale Item 112 (Nausea) — 1.4; 1.2; 0.9; 0.8 units…
Macular Degeneration
Primary: Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — 94.4; 95.1; 95.9; 95.1 percentage of patients
Common Cold
Primary: The Primary Efficacy Endpoint of This Study is the Incidence of Cold Illnesses. — 47.1; 43.9 cold illnesses per 100 subjects — p=>0.5000
Hepatitis B Infection
Primary: Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) < 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 48 — 72.5; 69.6 percentage of participants
Mitral Regurgitation
Primary: Left Ventricular End Diastolic Volume Indexed to Body Surface Area — 91.66; 95.74; 90.93; NA ml/m^2 — p=0.4568